Dacomitinib is a tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) involving epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution based on the results from the phase 3 trial ARCHER 1050.

Proton pump inhibitors (PPI) are widely used pharmacotherapies for gastroprotection in cancer patients but may limit the absorption of TKIs that require acidic environments for optimal dissolution, which has been shown in dedicated single-dose pharmacokinetic (PK) healthy volunteer studies for both dacomitinib and gefitinib.

This analysis evaluates the effect of concomitant PPI use on dacomitinib exposure and on both dacomitinib and gefitinib survival in patients treated in the ARCHER 1050 study.

With regard to PPI use, no significant differences were found for progression-free survival or overall survival in patients treated with dacomitinib or gefitinib, and no significant differences were found for dacomitinib exposure.

This analysis shows that PPI use in patients with NSCLC likely has minimal impact on dacomitinib efficacy despite decreased absorption observed in a PK study.